Microbiome Discovery and Mechanisms to Combat Antibiotic Resistance at Mucosal Surfaces

微生物组的发现和对抗粘膜表面抗生素耐药性的机制

基本信息

  • 批准号:
    10583457
  • 负责人:
  • 金额:
    $ 253.78万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-03-01 至 2026-02-28
  • 项目状态:
    未结题

项目摘要

Overall Project Summary The ability to control bacterial infections with antibiotics has been one of the most important public health advancements in human history. Before the discovery of antibiotics and vaccines, infectious disease was the leading cause of death and constituted nearly 50% of deaths in the US alone. Now, infectious diseases as a cause of death barely makes the top ten and we now treat most bacterial infections as a nuisance rather than life-threatening diseases. Unfortunately, this is rapidly changing with the emergence of antibiotic resistant bacterial pathogens. Ultimately, our ability to develop new antibiotics faster than resistance amongst pathogens emerges has failed and many scientists expect we will experience a return to a pre-antibiotic era in which we cannot treat what are now easy to cure bacterial infections. Therefore, novel, non-antibiotic approaches to controlling bacterial infections are required and need to be explored. The main theme of the BCM-CARBIRU is to use microbiome-based approaches to control bacterial infections at mucosal surfaces. We will investigate ecological principles of microbial community inhibition of pathogen colonization as well as the use of bacteriophage for precision elimination of bacterial pathogens. Both approaches have advantages over the use of antibiotics in that they leave the native microbiome largely intact, avoiding the elimination of beneficial microbes along with the pathogens targeted by antimicrobials. We propose three projects, supported by two scientific cores and the administrative core, to explore and optimize microbiome-based strategies for the prevention and treatment of bacterial infections. Project 1. Discovery and mechanistic understanding of phage activity and synergism at host mucosal surfaces. Project 2. Defined microbial communities to prevent and eradicate infection by antibiotic resistant pathogens. Project 3. Nasal microbial consortia combat antibiotic-resistant bacteria. We expect two main outcomes from the execution of these projects. First, we expect to define and understand the ecological principles that are key for microbial communities and bacteriophage to function to control pathogens at mucosal surfaces. Second, we expect to have identified actionable phage and microbial communities that will be available for testing in human clinical trials at the end of the project periods. Together, these projects will capitalize on protective measures at the mucosal surface, which have existed for millennia prior to modern medicine, as we enter the next era of microbiome-based therapies.
总体项目摘要 用抗生素控制细菌感染的能力一直是最重要的公共卫生之一 人类历史的进步。在发现抗生素和疫苗之前,传染病是人类最常见的疾病。 这是导致死亡的主要原因,仅在美国就占死亡人数的近50%。现在,传染病作为一种 死亡原因几乎没有排在前十位,我们现在把大多数细菌感染视为讨厌的东西,而不是 危及生命的疾病。不幸的是,随着抗生素耐药性的出现, 细菌病原体最终,我们开发新抗生素的能力比耐药性更快, 病原体的出现已经失败,许多科学家预计,我们将经历一个前抗生素时代的回归, 我们无法治疗现在很容易治愈的细菌感染。因此,新型非抗生素 需要并需要探索控制细菌感染的方法。的主旋律 BCM-CARBIRU是使用基于微生物组的方法来控制粘膜表面的细菌感染。 我们将探讨微生物群落抑制病原体定殖的生态学原理, 使用噬菌体精确消除细菌病原体。两种方法都有优点 抗生素的使用,因为它们在很大程度上保持了原生微生物组的完整性,避免了 有益微生物沿着抗菌剂靶向的病原体。我们提出三个项目, 在两个科学核心和行政核心的支持下,探索和优化基于微生物组的 预防和治疗细菌感染的策略。项目1。发现和机制 理解噬菌体活性和宿主粘膜表面的协同作用。项目2.确定的微生物 社区预防和根除耐抗生素病原体感染。项目3。鼻微生物 抵抗抗药性细菌的联合体。我们预计,这些措施的执行将产生两个主要结果。 项目首先,我们希望定义和理解微生物的关键生态原则, 群落和噬菌体的功能,以控制粘膜表面的病原体。第二,我们希望 已经确定了可用于人类临床测试的可操作噬菌体和微生物群落 在项目期结束时进行审判。这些项目将共同利用 粘膜表面,这已经存在了几千年前的现代医学,因为我们进入下一个时代, 基于微生物组的疗法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ROBERT A BRITTON其他文献

ROBERT A BRITTON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ROBERT A BRITTON', 18)}}的其他基金

Multi-method investigation and characterization of the ocular microbiome
眼部微生物组的多方法研究和表征
  • 批准号:
    10660691
  • 财政年份:
    2023
  • 资助金额:
    $ 253.78万
  • 项目类别:
Engineered probiotic for the treatment of autoimmune diseases
用于治疗自身免疫性疾病的工程益生菌
  • 批准号:
    10561101
  • 财政年份:
    2023
  • 资助金额:
    $ 253.78万
  • 项目类别:
Defined microbial communities to prevent and eradicate infection by AMR pathogens
定义微生物群落以预防和根除 AMR 病原体感染
  • 批准号:
    10357969
  • 财政年份:
    2021
  • 资助金额:
    $ 253.78万
  • 项目类别:
Admin Core - Britton
管理核心 - 布里顿
  • 批准号:
    10583458
  • 财政年份:
    2021
  • 资助金额:
    $ 253.78万
  • 项目类别:
Microbial and Phage Cultivation Core
微生物和噬菌体培养核心
  • 批准号:
    10583460
  • 财政年份:
    2021
  • 资助金额:
    $ 253.78万
  • 项目类别:
Microbiome Discovery and Mechanisms to Combat Antibiotic Resistance at Mucosal Surfaces
微生物组的发现和对抗粘膜表面抗生素耐药性的机制
  • 批准号:
    10357964
  • 财政年份:
    2021
  • 资助金额:
    $ 253.78万
  • 项目类别:
Microbial and Phage Cultivation Core
微生物和噬菌体培养核心
  • 批准号:
    10357966
  • 财政年份:
    2021
  • 资助金额:
    $ 253.78万
  • 项目类别:
Admin Core - Britton
管理核心 - 布里顿
  • 批准号:
    10357965
  • 财政年份:
    2021
  • 资助金额:
    $ 253.78万
  • 项目类别:
Defined microbial communities to prevent and eradicate infection by AMR pathogens
定义微生物群落以预防和根除 AMR 病原体感染
  • 批准号:
    10583468
  • 财政年份:
    2021
  • 资助金额:
    $ 253.78万
  • 项目类别:
Diet driven evolution of epidemic ribotypes of Clostridium difficile
饮食驱动艰难梭菌流行性核糖型的进化
  • 批准号:
    10053311
  • 财政年份:
    2017
  • 资助金额:
    $ 253.78万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 253.78万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 253.78万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 253.78万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 253.78万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 253.78万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 253.78万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 253.78万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 253.78万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 253.78万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 253.78万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了